Long-Term BIG I-98 Results Show Letrozole Benefit

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 3
Volume 16
Issue 3

Long-term (median, 51 months) follow-up data from the Breast International Group (BIG) I-98 trial support earlier findings that the aromatase inhibitor letrozole (Femara) is more effective than tamoxifen as initial postsurgery therapy for early breast cancer

BERN, Switzerland—Long-term (median, 51 months) follow-up data from the Breast International Group (BIG) I-98 trial support earlier findings that the aromatase inhibitor letrozole (Femara) is more effective than tamoxifen as initial postsurgery therapy for early breast cancer (J Clin Oncol 25:486-492, 2007).

Letrozole reduced recurrence risk by an additional 18% over tamoxifen and risk of distant metastases by an additional 19% in 4,922 postmenopausal women with hormone-sensitive early breast cancer randomized to 5 years of tamoxifen or letrozole (the current analysis did not include sequential treatment patients). Letrozole also significantly improved disease-free survival (DFS) (HR 0.82). In node-positive disease, letrozole reduced recurrence risk by a further 23% vs tamoxifen; in women who received chemotherapy, the reduction was a further 26%. A nonsignificant improvement in DFS also emerged in node-negative patients (12% vs 4% at the initial analysis).

Related Videos
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey K. Anders, MD, an expert on breast cancer
A panel of 4 experts on breast cancer seated at a long table
A panel of 4 experts on breast cancer seated at a long table
A panel of 4 experts on breast cancer seated at a long table
Related Content